97.51 0.00 (0.00%)
After hours: 7:00PM EDT
|Bid||96.96 x 800|
|Ask||101.50 x 1300|
|Day's range||97.21 - 99.60|
|52-week range||50.91 - 99.82|
|PE ratio (TTM)||N/A|
|Earnings date||6 Aug 2018 - 10 Aug 2018|
|Forward dividend & yield||N/A (N/A)|
|1y target est||99.25|
Agios Pharmaceuticals, Inc. (AGIO), initiates a phase III ACTIVATE study which will evaluateits lead rare genetic diseases candidate, AG-348 in patients with PK deficiency who do not receive regular blood transfusions.
Agios Pharmaceuticals (AGIO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Agios (AGIO) incurs wider-than-expected loss and misses revenue estimates in Q1. The first quarter highlights the FDA's acceptance of the NDA for Tibsovo.
The Cambridge, Massachusetts-based company said it had a loss of $1.63 per share. The results did not meet Wall Street expectations. The average estimate of four analysts surveyed by Zacks Investment Research ...
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investor focus is expected to remain on the company's pipeline in the first quarter.
In 4Q17, Jazz Pharmaceuticals’ (JAZZ) Vyxeos (daunorubicin and cytarabine) generated revenues of $24 million compared to $10 million in 3Q17. In fiscal 2017, Vyxeos reported net revenues of $34 million.
The FDA approval for Agios' (AGIO) only marketed drug, Idhifa, augurs well for long-term growth. The company is also well on progress track with its lead candidate, ivosidenib, for R/R AML.
The Zacks Analyst Blog Highlights: Agios Pharmaceuticals, BioMarin Pharmaceutical, Vertex Pharmaceuticals and Incyte
Novartis and Alexion announce respective acquisitions of AveXis and Wilson Therapeutics for a pipeline boost. We suggest four stocks as hot acquisition picks this year.
In December 2017, the FDA approved Omeros’s supplemental new drug application for expanding the use of Omidria for pediatric use. Omidria prevents intraoperative miosis and also reduces post-operative pain for individuals undergoing cataract surgery and intraocular lens replacement. In January 2018, the European Medicines Agency’s Committee for Orphan Medicinal Products responded positively to Omeros’s application for orphan drug status for OMS721 for the treatment of primary immunoglobulin A nephropathy.
Agios (AGIO) share price shoots up on probable acquisition by other biggies in the biotech industry. This optimism follows the news of Novartis striking a deal to buy gene therapy company, AveXis.
Agios Pharmaceuticals (AGIO) is a biopharmaceutical company with therapeutic focus areas of cancer and rare genetic diseases. Of the nine analysts covering Agios Pharmaceuticals (AGIO) in March 2018, one analyst gave it a “strong buy” rating, six analysts gave it a “buy” rating, and two analysts gave it a “hold” rating.
Agios (AGIO) reports wider-than-expected loss in the fourth quarter of 2017. Revenues fall short of expectations. The top line also declines year over year.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of $1.81. The results fell short of Wall Street expectations. The average estimate of five analysts surveyed by Zacks ...
Agios' (AGIO) pipeline progress appears consistently impressive. Notably, investors' focus will remain on the company's pipeline on fourth-quarter earnings call.
Last year's FDA approval of Agios' (AGIO) only marketed drug Idhifa and its rapid progress on a robust pipeline during the period drive the share price consistently.